Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
ZANVASTRO received early FDA approval as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. The pivotal trial reported motor function stabilization and a favorable safety profile.
ZANVASTRO (zilganersen) is now FDA-approved as the first disease-modifying therapy for Alexander disease in both children and adults, citing pivotal trial data showing motor function stabilization and a favorable safety profile.